Skip to content
Triangle logo TriangleGet started
← Study library

NCT01084083 · CITED IN SOURCE DOCUMENTS

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2023-06-28

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well they work when followed by cetuximab and two different doses of intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

24-month Progression-free Survival

→

outcome · POSTED

24-months Overall Survival

→

outcome · POSTED

Primary Clinical Response Rate

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx as determined by Hematoxylin and eosin (H\&E) staining * Newly diagnosed disease * Resectable disease OR disease that is expected to become resectable after study treatment * Stage III, IVA, or IVB disease as determined by imaging studies (computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI) required) and a complete head and neck exam * Paraffin-embedded tumor specimen available for central confirmation of HPV-associated disease as determined by H\&E staining and in-situ hybridization (ISH) for HPV-16 and immunohistochemistry (IHC) for p16 * HPV-associated disease is defined as p16 IHC-positive and/or HPV-16 ISH-positive * Non-HPV-associated disease is defined as p16 IHC-negative * NOTE: If there is limited tumor material, p16 IHC will be performed before HPV-16 ISH * Measurable disease of the primary tumor or nodes by clinical and radiographic methods, defined as a lesion that is ≥ 2 cm in at least one dimension by clinical exam AND by radiographic exam with CT scan or MRI (or a lesion that is ≥ 1 cm in at least one dimension if the radiographic exam utilizes spiral CT scan) * No primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical spine * No evidence of distant metastases * Eastern Cooperative Oncology Group performance status 0-1 * Granulocytes ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Total serum bilirubin ≤ 1.5 mg/dL * Creatinine clearance ≥ 60 mL/min * Negative pregnancy test * Fertile patients must use effective contraception * No history of another malignancy (except for carcinoma in situ of the cervix and/or nonmelanomatous skin cancer) unless it has been curatively treated and the patient has been disease-free for ≥ 2 years * Patients with any of the following within the past 6 months are eligible provided they have been evaluated by a cardiologist and/or neurologist before study entry: * New York Heart Association (NYHA) class III-IV congestive heart failure * Cerebrovascular accident or transient ischemic attack * Unstable angina * Myocardial infarction (with or without ST elevation) Exclusion Criteria: * Prior chemotherapy * Prior radiotherapy above the clavicles * Prior surgery with curative intent for this disease (complete head and neck exam with biopsy allowed) * Prior therapy specifically and directly targeting the EGFR pathway * Prior severe infusion reaction to a monoclonal antibody * Uncontrolled diabetes, uncontrolled infection despite antibiotics, or uncontrolled hypertension within the past 30 days * Concurrent illness likely to interfere with study therapy or to prevent surgical resection * Pregnant or nursing
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
    intervention Names
    1. Biological: cetuximab
    2. Radiation: intensity-modulated radiation therapy (IMRT)
    3. Drug: Paclitaxel
    4. Drug: Cisplatin
    label
    Group 1
    type
    EXPERIMENTAL
  2. description
    After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
    intervention Names
    1. Biological: cetuximab
    2. Radiation: intensity-modulated radiation therapy (IMRT)
    3. Drug: Paclitaxel
    4. Drug: Cisplatin
    label
    Group 2
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Group 1
    2. Group 2
    description
    Given IV
    name
    cetuximab
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Group 1
    2. Group 2
    description
    Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
    name
    intensity-modulated radiation therapy (IMRT)
    type
    RADIATION
  3. arm Group Labels
    1. Group 1
    2. Group 2
    description
    Given IV, 90 mg/m\^2 on days 1, 8 and 15
    name
    Paclitaxel
    other Names
    1. Abraxane, Taxol
    type
    DRUG
  4. arm Group Labels
    1. Group 1
    2. Group 2
    description
    Given IV, 75 mg/m\^2 on day 1
    name
    Cisplatin
    other Names
    1. Platinol
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
90
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    24-month progression-free survival is defined as the proportion of patients who were alive and progression-free at 24 months post registration. The primary study population for this endpoint is patients who were confirmed post-induction clinical complete response (CR) at their primary sites and subsequently received 5400 cGy radiation therapy to their primary sites.
    measure
    24-month Progression-free Survival
    time Frame
    assessed within 14 days after delivery of the third cycle of induction therapy, and 8 weeks and 6 months after completion of concurrent therapy, then every 6 months until progression or until 3 years from study entry
secondary Outcomes
  1. description
    OS was defined as the time from registration to death, or censored at last date known alive. Kaplan-Meier method was used to estimate the overall survival rate at 24 months.
    measure
    24-months Overall Survival
    time Frame
    assessed within 14 days after delivery of the third cycle of induction therapy, and 8 weeks and 6 months after completion of concurrent therapy, then every 6 months until progression or until 3 years from study entry
  2. description
    Primary clinical response rate is defined as the proportion of patients with complete response or partial response at their primary sites after induction therapy. Response status for the primary site was classified by clinical examination using endoscopy. If, however, the clinical response status of the primary was unclear based on endoscopy, then the CT or MRI (required at the end of induction) was used to determine status of the primary. If clinical and radiological evaluation of the primary was unclear, a biopsy was considered at the discretion of the treating physician.
    measure
    Primary Clinical Response Rate
    time Frame
    assessed within 14 days after delivery of the third cycle of induction therapy
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well they work when followed by cetuximab and two different doses of intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery.
detailed Description
OBJECTIVES: Primary * To evaluate the efficacy of induction therapy comprising paclitaxel, cisplatin, and cetuximab followed by cetuximab in combination with low-dose or standard-dose intensity-modulated radiotherapy, as measured by 2-year progression-free survival (PFS), in patients with human papillomavirus(HPV)-associated resectable stage III-IVB squamous cell carcinoma of the oropharynx. Secondary * To assess overall survival. * To evaluate the objective response, local control, and metastatic rate. * To evaluate early and late toxicities of treatment. Tertiary * To evaluate quality of life and speech and swallowing function as measured by Functional Assessment of Cancer Therapy - General (FACT-G), Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN), and Vanderbilt Head and Neck Symptom Survey (VHNSS). * To assess the effect of treatment-induced fatigue on general physical functioning in patients with head and neck cancer. * To correlate functional decline with clinical, physical, and biologic correlatives. * To evaluate radiation-resistance markers, including ERCC1 single nucleotide polymorphism and protein expression, and to correlate them with treatment efficacy. * To demonstrate the usefulness of biomarkers, including ERCC1, epidermal growth factor receptor (EGFR), cytokine and chemokine markers, and plasma transforming growth factor alpha (TGFA) and transforming growth factor beta (TGFB) levels, in predicting progression-free survival (PFS) and other outcome parameters. * To evaluate the correlation between the efficacy of cetuximab and polymorphisms in FcγR-receptors. * To evaluate functional outcome and biological parameters, including telomere length, angiotensin-converting enzyme polymorphism, and C-reactive protein level. OUTLINE: This is a multicenter study. * Induction therapy: Patients receive cisplatin intravenously (IV) over 1 hour on day 1 and paclitaxel IV over 3 hours and cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for 3 courses. Patients then undergo evaluation of response to induction therapy. Patients with a clinical complete response (CR) at the primary tumor site proceed to group 1 of concurrent radiotherapy and cetuximab. Patients with a clinical partial response (PR) or stable disease (SD) at the primary tumor site or those with grossly positive disease at the primary tumor site proceed to group 2 of concurrent radiotherapy and cetuximab. * Concurrent radiotherapy and cetuximab: Treatment begins 14-21 days after the last day of induction therapy. * Group 1 (CR): Patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks. * Group 2 (PR, SD, or grossly positive disease): Patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks. Patients complete questionnaires assessing fatigue, physical function, weight loss, quality of life, head and neck symptom burden, and speech and swallowing function at baseline and at 1, 6, 12, and 24 months after completion of study treatment. Tumor tissue and serum samples may be collected periodically for correlative laboratory studies. After completion of study treatment, patients are followed up periodically for 3 years. PROJECTED ACCRUAL: 83 patients
Source references
references
  1. citation
    Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.
    pmid
    28029303
    type
    RESULT
  2. citation
    Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Nov;25(11):2101-2115. doi: 10.1093/annonc/mdu265. Epub 2014 Jul 23.
    pmid
    25057165
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-981cfb9efb8f961d98cf
      requested nct id
      NCT01084083
      primary nct id
      NCT01084083
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      31f0b7d3c9f8a622c00428041f6c731a10acf24c59277b3cd1a8fb560d317e44
      payload sha256
      d656729e7df05e816830d01f792fabdfc48478fa27fd8077513d550e5176d8a8
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-981cfb9efb8f961d98cf
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01084083
      occurrences
      1. context exact
        y of neoadjuvant chemotherapy using cisplatin, paclitaxel, and cetuximab in patients with HPV-associated oropharyngeal SCC (ECOG 1308 [<a href="/clinicaltrials/NCT01084083">NCT01084083</a>]), patients who achieved a complete clinical response to three cycles of neoadjuvant chemotherapy received reduced-dose IMRT of 54 Gy with we
        end
        131873
        exact text
        NCT01084083
        start
        131862
      2. context exact
        ant chemotherapy using cisplatin, paclitaxel, and cetuximab in patients with HPV-associated oropharyngeal SCC (ECOG 1308 [<a href="/clinicaltrials/NCT01084083">NCT01084083</a>]), patients who achieved a complete clinical response to three cycles of neoadjuvant chemotherapy received reduced-dose IMRT of 54 Gy with weekly cetuxima
        end
        131886
        exact text
        NCT01084083
        start
        131875
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/2f62e0aa018c9f4893.html
      source file sha256
      31f0b7d3c9f8a622c00428041f6c731a10acf24c59277b3cd1a8fb560d317e44
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:46.804056+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      7c085a9f6221e622687066d2881d8d5d699cd85217f4b322d2597bd617a74997
      source title
      Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice